Clinical trial
Study of Safety and Efficacy of Letrozole Monotherapy as Second-line Endocrine…
NCT00237198 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00237198 |
|---|---|
| Title | Study of Safety and Efficacy of Letrozole Monotherapy as Second-line Endocrine Therapy in Postmenopausal Patients With Advanced Breast Cancer Who Received Previous Anti-estrogen Treatment |
| Official title | Study of Safety and Efficacy of Letrozole Monotherapy as Second-line Endocrine Therapy in Postmenopausal Patients With Advanced Breast Cancer Who Received Previous Anti-estrogen Treatment |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Collaborators | Chugai Pharmaceutical Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Postmenopausal Women With Advanced Breast Cancer |
| Intervention type | Drug |
| Interventions | Letrozole |
| Enrollment | 47 |
| Start date | Mar 1, 2004 |
| Primary completion | Jul 1, 2006 |
| First posted | Oct 12, 2005 |
| Last update posted | Feb 23, 2017 |
| Countries | Japan |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: